|
Market Closed -
Hong Kong S.E.
09:08:31 24/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 11.39 HKD | -2.40% |
|
+1.06% | -4.85% |
| 09-04 | Simcere Pharma's Yingmule Gets China Marketing Approval for RSV Prevention | MT |
| 09-03 | Simcere Pharmaceutical Group Limited Announces Approval for Marketing of Yingmule in China | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- 2096 Stock
- Consensus Simcere Pharmaceutical Group Limited
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
